Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

Today we learned that USP has extended the comment period for its proposed changes to chapters <795> and <797>.

APC, APhA, and NCPA sent a joint letter to USP in December asking for the comment period to be extended through the end of April. USP has agreed to extend it through March 17.

We welcome this extension, and we thank USP for granting it. We’ll use this additional time to continue to educate compounders and prescribers about the potential impact these proposed BUDs would have on their patients.

Speaking of which, please remember that APC is holding a 30-minute briefing for prescribers this coming Thursday, January 20, to educate them about the complications such BUDs could bring to patient care. Please let the prescribers you work with know about this briefing — we need to get the word out quickly. Thank you!